GILEAD SCIENCES, INC.

(GILD)
  Report
Delayed Nasdaq  -  04:00 2022-08-17 pm EDT
66.02 USD   -0.47%
08/17Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care
BU
08/16Gilead Sciences Says Veklury Demonstrates Continued In Vitro Antiviral Activity Against Omicron
MT
08/16Gilead Sciences and a Coalition of LGBTQ+ and Human Rights-Focused Organizations Mobilize to Address Monkeypox Public Health Emergency
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Sciences, Inc. Announces Investigational Lenacapavir Receives Positive Chmp Opinion for People with Multi-Drug Resistant HIV

06/24/2022 | 08:00am EDT

Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for investigational lenacapavir for the treatment of HIV-1 infection, in combination with other antiretroviral(s), in adults with multi-drug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen. The CHMP positive opinion is a scientific recommendation to the European Commission (EC) to grant marketing authorization in Europe and will be reviewed by the EC, which has the authority to authorize medicines in the 27 Member States of the European Union, as well as Norway, Iceland and Liechtenstein. The final European Commission decision is expected later this year. The positive opinion is supported by data from the Phase 2/3 CAPELLA trial, a double-blinded, placebo-controlled global multicenter study designed to evaluate the antiviral activity of lenacapavir administered every six months as a subcutaneous injection, in combination with other antiretroviral(s), in heavily treatment-experienced people with multi-drug resistant HIV-1 infection. In this patient population of high unmet medical need, 81% (n=29/36) of participants receiving lenacapavir in addition to an optimized background regimen achieved an undetectable viral load (<50 copies/mL) at Week 26. Additionally, CAPELLA participants achieved a mean increase in CD4 count of 81 cells/µL. The New England Journal of Medicine published the primary outcome results of the CAPELLA trial in its May 11, 2022 issue - Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection. Through Week 26, lenacapavir was generally well tolerated, with no serious adverse events related to lenacapavir as determined by the study investigator. The most common adverse events observed in the trial were injection-site reactions. Lenacapavir is an investigational compound and is not approved by any regulatory authority for any use and its safety and efficacy are not established. There is no cure for HIV or AIDS. Lenacapavir is Gilead's potential first-in-class, investigational long-acting HIV-1 capsid inhibitor in development for the treatment of HIV-1 infection. The safety, efficacy and dosing of Gilead's investigational, long-acting HIV-1 capsid inhibitor lenacapavir are being evaluated in multiple ongoing clinical studies. Lenacapavir's multi-stage mechanism of action is distinguishable from currently approved classes of antiviral agents and is designed to provide a new avenue for the development of long-acting therapy options for people with or at risk for HIV-1. While most antivirals act on just one stage of viral replication, lenacapavir is designed to inhibit HIV-1 at multiple stages of its lifecycle and has no known cross resistance to other existing drug classes. If authorized, lenacapavir would be the only HIV-1 treatment option administered twice yearly. CAPELLA is a Phase 2/3, double-blinded, placebo-controlled global multicenter study designed to evaluate the antiviral activity of lenacapavir administered every six months as a subcutaneous injection in heavily treatment-experienced people with multi-drug resistant HIV-1 infection. CAPELLA includes men and women with HIV-1 and is being conducted at research centers in North America, Europe and Asia. In CAPELLA, 36 participants with multi-class HIV-1 drug resistance and a detectable viral load while on a failing regimen were randomly allocated to receive oral lenacapavir or placebo in a 2:1 ratio for 14 days, in addition to continuing their failing regimen (functional monotherapy). An additional 36 participants were enrolled in a separate treatment cohort. Both cohorts are part of the ongoing maintenance period of the study evaluating the safety and efficacy of subcutaneous lenacapavir administered every six months in combination with an optimized background regimen. The primary endpoint was the proportion of participants randomly allocated to receive lenacapavir or placebo for 14 days, in addition to continuing their failing regimen, achieving =0.5 log10 copies/mL reduction from baseline in HIV-1 RNA at the end of the functional monotherapy period. Following the 14-day functional monotherapy period, participants randomly allocated to receive lenacapavir or placebo, in addition to continuing their failing regimen, started open-label lenacapavir and an optimized background regimen, while those enrolled in a separate treatment cohort received open-label lenacapavir and an optimized background regimen on Day 1. This ongoing maintenance period of the study is evaluating the additional trial endpoints of safety and efficacy of subcutaneous lenacapavir administered every six months in combination with an optimized background regimen.


© S&P Capital IQ 2022
All news about GILEAD SCIENCES, INC.
08/17Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier Un..
BU
08/16Gilead Sciences Says Veklury Demonstrates Continued In Vitro Antiviral Activity Against..
MT
08/16Gilead Sciences and a Coalition of LGBTQ+ and Human Rights-Focused Organizations Mobili..
AQ
08/16Everest Medicines Terminates Cancer Drug Licensing Deal with Immunomedics
MT
08/16Gilead to Acquire Remaining Worldwide Rights of Trodelvy
AQ
08/16Gilead Sciences Unit Enters Into Licensing Agreement With Everest Medicines for Trodelv..
MT
08/15Gilead to Acquire Remaining Worldwide Rights of Trodelvy®
BU
08/15US Stocks Start Week Higher as Tesla Helps Lift Tech Sector
MT
08/15US Stocks Start Week Higher as Tech, Megacap Growth Stocks Gain
MT
08/15Unity Software, Turquoise Hill fall; Gilead, Moderna rise
AQ
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 25 182 M - -
Net income 2022 3 913 M - -
Net Debt 2022 16 314 M - -
P/E ratio 2022 20,8x
Yield 2022 4,42%
Capitalization 82 747 M 82 747 M -
EV / Sales 2022 3,93x
EV / Sales 2023 3,91x
Nbr of Employees 14 400
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Last Close Price 66,02 $
Average target price 70,57 $
Spread / Average Target 6,88%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Kevin E. Lofton Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.-9.08%82 747
VERTEX PHARMACEUTICALS37.98%76 740
REGENERON PHARMACEUTICALS, INC.0.76%68 030
WUXI APPTEC CO., LTD.-22.47%39 407
BIONTECH SE-41.02%36 949
GENMAB A/S0.99%23 720